Agios Pharmaceuticals, Inc.
DE ˙ DB ˙ US00847X1046
€ 23,40 ↑0.80 (3.54%)
2026-06-04
PREÇO DA AÇÃO
SecurityDE:8AP / Agios Pharmaceuticals, Inc.
InstitutionQuest Partners LLC
Latest Disclosed Ownership11,963 shares
Latest Disclosed Value $ 325,633
Quest Partners LLC reports 121.09% increase in ownership of 8AP / Agios Pharmaceuticals, Inc.

On February 9, 2026 - Quest Partners LLC filed a 13F-HR form disclosing ownership of 11,963 shares of Agios Pharmaceuticals, Inc. (DE:8AP) valued at $275,149 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 3, 2025 disclosing 5,411 shares of Agios Pharmaceuticals, Inc.. This represents a change in shares of 121.09% during the quarter. The current value of the position is $279,934 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-09 2025-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 11,963 6,552 121.09 326 49.77 0.0182
2025-11-03 2025-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 5,411 4,742 708.82 217 886.36 0.0142
2025-07-31 2025-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 669 296 79.36 22 120.00 0.0022
2025-05-14 2025-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 373 -4,167 -91.78 11 -93.29 0.0012
2025-02-07 2024-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 4,540 2,338 106.18 149 53.61 0.0198
2024-11-07 2024-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 2,202 1,283 139.61 98 148.72 0.0087
2024-08-06 2024-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 919 919 40 0.0054
2024-05-09 2024-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 0 -1,863 -100.00 0 -100.00
2024-02-09 2023-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 1,863 1,863 41 0.0088
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.